Education
- 2012–2018, Ajou University, Department of Molecular Science and Technology, Ph.D.
- 2005–2012, Ajou University, Department of Applied Chemistry and Biological Engineering, B.S.
Career
- 2026-present| Seoul National University| School of Transdisciplinary Innovations &College of Pharmacy | Assistant Professor
- 2026.01 |GLPG US Inc. | Cell & Antibody Therapy Discovery | Head Principal Scientist
- 2023–2025| GLPG US Inc. | Cell & Antibody Therapy Discovery | Principal Scientist
- 2021–2023| University of Pittsburgh School of Medicine | Department of Medicine,Division of Infectious Diseases | Research Assistant Professor (NIHUM1AI164565, Co-Investigator)
- 2018–2021| University of Pittsburgh School of Medicine | Center for AntibodyTherapeutics, Department of Medicine | Postdoctoral Associate
Research Field
– Antibody libraries with display technologies
– Immunotherapeutic development
– Protein & Antigen Engineering
– Immunotherapeutic development
– Protein & Antigen Engineering
Representative
Publication
- Shin, S.; Kim, Y.-J.; Macatangay, B.J.C.; Cyktor, J.C.; Hines, M.G.; Mellors, J.W.; Dimitrov, D.S.; Li, W.; Baek, D.-S. | Discovery and pre-clinical evaluation of antibodies and bispecific engagers targeting the NKG2A inhibitory receptor. | Science Advances | 2026
- Shin, S.; Baek, D.-S.; Mellors, J.W.; Dimitrov, D.S.; Li, W. | Development of Fully Human Antibodies Targeting SIRPαand PLA2G7 for Cancer Therapy. | Antibodies | 2025
- Chu, X.; Shin, S.; Baek, D.-S.; Zhang, L.; Conard, A.; Shi, M.; Kim, Y.-J.; Adams, C.; Hines, M.G.; Liu, X.; Chen, C.; Sun, Z.; Jelev, D.V.; Mellors, J.W.; Dimitrov, D.S.; Li, W.| Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer. | mAbs | 2024
- Saha, N.; Baek, D.-S.;Mendoza, R.P.; Robev, D.; Xu, Y.; Goldgur, Y.; De La Cruz, M.J.; De Stanchina, E.; Janes, P.W.; Xu, K.; Dimitrov, D.S.; Nikolov, D.B. | Fully human monoclonal antibody targeting activated ADAM10 on colorectal cancer cells. | Biomedicine & Pharmacotherapy | 2023
- Kim, Y.-J.; Li, W.; Zhelev, D.V.; Mellors, J.W.; Dimitrov, D.S.; Baek, D.-S. | Chimeric antigen receptor (CAR)-T cells are effective against CEACAM5-expressing non-small cell lung cancer cells resistant to antibody-drug conjugates.| Frontiers in Oncology | 2023
- Baek, D.-S.; Kim, Y.-J.; Vergara, S.; Conard, A.; Adams, C.; Calero, G.; Ishima, R.; Mellors, J.W.; Dimitrov, D.S. | A highly specific fully human antibody and CAR-T cells targeting CD66e effectively kill cancer cells. | Cancer Letters | 2022
